Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine

Journal of the American College of Cardiology

Volumn 64, Issue 1, 2014, Pages 83-99

  Maron, Barry J ^a   Ommen, Steve R ^b   Semsarian, Christopher ^c   Spirito, Paolo ^d   Olivotto, Iacopo ^e   Maron, Martin S ^f  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b MAYO CLINIC   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d GALLIERA HOSPITAL   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

atrial fibrillation; cardiac surgery; echocardiography; genetics; heart failure; hypertrophic cardiomyopathy; implantable defibrillators; magnetic resonance imaging; sudden death

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; SOTALOL; VERAPAMIL;

ABLATION THERAPY; ATHLETE; CARDIAC IMAGING; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL FEATURE; CRYOABLATION; DEFIBRILLATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FAMILY ASSESSMENT; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUDDEN CARDIAC DEATH; TREATMENT INDICATION; ANIMAL; CARDIOLOGY; ECHOCARDIOGRAPHY; FORECASTING; GENETICS; HEART SURGERY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; SUDDEN DEATH; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; CARDIAC SURGERY; ECHOCARDIOGRAPHY; GENETICS; HEART FAILURE; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE DEFIBRILLATORS; MAGNETIC RESONANCE IMAGING; SUDDEN DEATH;

ANIMALS; CARDIOLOGY; CARDIOMYOPATHY, HYPERTROPHIC; FORECASTING; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84903836626     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.05.003     Document Type: Review

References (119)

1. D. Teare Asymmetric hypertrophy of the heart in young adults Br Heart J 20 1958 1 8
2. E. Braunwald, C.T. Lambrew, and S.D. Rockoff et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients Circulation 30 1964 3 119
3. E. Braunwald, E.C. Brockenbrough, and A.G. Morrow Hypertrophic subaortic stenosis - a broadened concept Circulation 26 1962 161 165
4. B.J. Maron, and M.S. Maron Hypertrophic cardiomyopathy Lancet 381 2013 242 255
5. P. Spirito, C.E. Seidman, and W.J. McKenna et al. The management of hypertrophic cardiomyopathy N Engl J Med 336 1997 775 785
6. B.J. Maron Hypertrophic cardiomyopathy: a systematic review JAMA 287 2002 1308 1320
7. B.J. Maron Hypertrophic cardiomyopathy: an important global disease Am J Med 116 2004 63 65
8. B.J. Maron Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy Circulation 121 2010 445 456
9. M.S. Maron, B.J. Maron, and C. Harrigan et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance J Am Coll Cardiol 54 2009 220 228
10. B.J. Maron Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy Circulation 116 2007 196 206
11. B.J. Maron, M.S. Maron, and E.D. Wigle et al. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy J Am Coll Cardiol 54 2009 191 200
12. B.J. Maron, M.S. Maron, and C. Semsarian Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives J Am Coll Cardiol 60 2012 705 715
13. B.J. Maron, J.A. Dearani, and S.R. Ommen et al. The case for surgery in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 2044 2053
14. B.J. Maron, S.A. Casey, and L.C. Poliac et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort JAMA 281 1999 650 655
15. B.J. Maron, I. Olivotto, and P. Spirito et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population Circulation 102 2000 858 864
16. M.S. Maron, I. Olivotto, and A.G. Zenovich et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction Circulation 114 2006 2232 2239
17. M.S. Maron, I. Olivotto, and C. Harrigan et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represents a primary phenotypic expression of hypertrophic cardiomyopathy Circulation 124 2011 40 47
18. K.M. Harris, P. Spirito, and M.S. Maron et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy Circulation 114 2006 216 225
19. M.S. Maron, J.J. Finley, and J.M. Bos et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy Circulation 118 2008 1541 1544
20. P.M. Elliott, J. Poloniecki, and S. Dickie et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients J Am Coll Cardiol 36 2000 2212 2218
21. M.S. Maron, I. Olivotto, and S. Betocchi et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy N Engl J Med 348 2003 295 303
22. H.G. Klues, W.C. Roberts, and B.J. Maron Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction Circulation 84 1991 1188 1197
23. B.J. Maron, J.G. Seidman, and C.E. Seidman Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy J Am Coll Cardiol 44 2004 2125 2132
24. B.J. Maron, L. Yeates, and C. Semsarian Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy Am J Cardiol 107 2011 604 608
25. C.E. Seidman, and J.G. Seidman Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history Circ Res 108 2011 743 750
26. B.J. Maron, H. Niimura, and S.A. Casey et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein-C gene mutations J Am Coll Cardiol 38 2001 315 321
27. B.J. Maron, W.-K. Shen, and M.S. Link et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy N Engl J Med 342 2000 365 373
28. B.J. Maron, P. Spirito, and W.-K. Shen et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy JAMA 298 2007 405 412
29. B.J. Maron, P. Spirito, and M.J. Ackerman et al. Prevention of sudden cardiac death with the implantable cardioverter-defibrillator in children and adolescents with hypertrophic cardiomyopathy J Am Coll Cardiol 61 2013 1527 1535
30. A.F. Schinkel, P.A. Vriesendorp, and E.J. Sijbrands et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis Circ Heart Fail 5 2012 552 559
31. P.A. Vriesendorp, A.F. Schinkel, and J. Van Cleemput et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications Am Heart J 166 2013 496 502
32. C. O'Mahony, F. Jichi, and M. Pavlou et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD) Eur Heart J 2013 Oct 14 [E-pub ahead of print]
33. C. O'Mahony, M. Tome-Esteban, and P.D. Lambiase et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy Heart 99 2013 534 541
34. I. Christiaans, K. van Engelen, and I.M. van Langen et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers Europace 12 2010 313 321
35. R.H. Chan, B.J. Maron, and I. Olivotto et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy Circulation 2014 10.1161/CirculationAHA.113.007094 In press
36. S.R. Ommen, B.J. Maron, and I. Olivotto et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 46 2005 470 476
37. P. Sorajja, S.R. Ommen, and D.R. Holmes Jr. et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy Circulation 126 2012 2374 2380
38. B.J. Maron, E.J. Rowin, and S.A. Casey et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy over 60 years of age Circulation 127 2013 585 593
39. B.J. Maron, W.J. McKenna, and G.K. Danielson et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J Am Coll Cardiol 42 2003 1687 1713
40. B.J. Gersh, B.J. Maron, and R.O. Bonow et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 58 2011 e212 e260
41. E.J. Rowin, M.S. Maron, and S.A. Casey et al. Evidence for reduced mortality in an adult cohort with hypertrophic cardiomyopathy Circulation 128 2013 A13294
42. B.J. Maron, and E. Braunwald Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease Circulation 126 2012 1640 1644
43. B.J. Maron, J.M. Gardin, and J.M. Flack et al. Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study Circulation 92 1995 785 789
44. B.J. Maron, K.P. Carney, and H.M. Lever et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy J Am Coll Cardiol 41 2003 974 980
45. I. Olivotto, M.S. Maron, and A.S. Adabag et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy J Am Coll Cardiol 46 2005 480 487
46. A.S. Adabag, M.A. Kuskowski, and B.J. Maron Determinants for clinical diagnosis of hypertrophic cardiomyopathy Am J Cardiol 98 2006 1507 1511
47. T. Knickelbine, R.J. Lesser, and E.R. Brandenburg et al. Identification of unexpected nonatherosclerotic cardiovascular disease with CT angiography J Am Coll Cardiol Img 2 2009 1085 1092
48. J.M. Bos, J.A. Towbin, and M.J. Ackerman Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy J Am Coll Cardiol 54 2009 201 211
49. J. Ingles, T. Sarina, and L. Yeates et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy Genet Med 15 2013 972 977
50. H. Niimura, L.L. Bachinski, and S. Sangwatanaroj et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy N Engl J Med 338 1998 1248 1257
51. B.J. Maron, and C. Semsarian Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy Eur Heart J 31 2010 1551 1553
52. B. Gray, J. Ingles, and C. Semsarian Natural history of genotype positive - phenotype negative patients with hypertrophic cardiomyopathy Int J Cardiol 152 2011 258 259
53. C.Y. Ho, N.K. Sweitzer, and B. McDonough et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy Circulation 105 2002 2992 2997
54. C.Y. Ho, B. Lopez, and O.R. Coelho-Filho et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy N Engl J Med 363 2010 552 563
55. M.S. Maron, E.J. Rowin, and D. Lin et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy Circ Cardiovasc Imaging 5 2012 441 447
56. I. Christiaans, E. Birnie, and G.J. Bonsel et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy Eur Heart J 32 2011 1161 1170
57. B.J. Maron, M.J. Ackerman, and R.A. Nishimura et al. Task force 4: hypertrophic cardiomyopathy and other cardiomyopathies, mitral valve prolapse, myocarditis and Marfan syndrome J Am Coll Cardiol 45 2005 1340 1345
58. J. Ingles, and C. Semsarian Conveying a probabilistic gene result to families with an inherited heart disease Heart Rhythm 11 2014 1073 1078
59. K.J. Das, J. Ingles, and R.D. Bagnall et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment Genet Med 16 2014 286 293
60. B.J. Maron, W.C. Roberts, and M. Arad et al. Clinical outcome and phenotypic expression in LAMP 2 cardiomyopathy JAMA 301 2009 1253 1259
61. B.J. Maron, T.S. Haas, and C. Kitner et al. Onset of apical hypertrophic cardiomyopathy in adulthood Am J Cardiol 108 2011 1783 1787
62. H.G. Klues, A. Schiffers, and B.J. Maron Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients J Am Coll Cardiol 26 1995 1699 1708
63. W.L. Henry, C.E. Clark, and S. Epstein Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS Circulation 47 1973 225 233
64. C. Rickers, N.M. Wilke, and M. Jerosch-Herold et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy Circulation 112 2005 855 861
65. P. Spirito, P. Bellone, and K.M. Harris et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy N Engl J Med 342 2000 1778 1785
66. M.S. Maron, T.H. Hauser, and E. Dubrow et al. Right ventricular involvement in hypertrophic cardiomyopathy Am J Cardiol 100 2007 1293 1298
67. I. Olivotto, M.S. Maron, and C. Autore et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy J Am Coll Cardiol 52 2008 559 566
68. I. Olivotto, B.J. Maron, and B. Tomberli et al. Obesity and its association with phenotype and clinical course of hypertrophic cardiomyopathy J Am Coll Cardiol 62 2013 449 457
69. B.J. Maron, S. Casey, and T.S. Haas et al. Hypertrophic cardiomyopathy with longevity into the tenth decade of life Am J Cardiol 109 2012 1341 1347
70. P.M. Shah, A.G. Adelman, and E.D. Wigle et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy Circ Res 35 Suppl II 1974 179 195
71. T. Hardarson, and C.S. De la Calzada et al. Prognosis and mortality of hypertrophic obstructive cardiomyopathy Lancet 2 1973 1462 1467
72. W.J. McKenna, and J.E. Deanfield Hypertrophic cardiomyopathy: an important cause of sudden death Arch Dis Child 59 1984 971 975
73. P. Spirito, F. Chiarella, and L. Carratino et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population N Engl J Med 320 1989 749 755
74. B.J. Maron Hypertrophic cardiomyopathy centers Am J Cardiol 104 2009 1158 1159
75. B.J. Maron, H. Rastegar, and J.E. Udelson et al. Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative Am J Cardiol 112 2013 1512 1515
76. P. Spirito, C. Autore, and C. Rapezzi et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy Circulation 119 2009 1703 1710
77. P. Spirito, C. Autore, and F. Formisano et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign clinical presentation and without risk factors Am J Cardiol 113 2014 1550 1555
78. M.S. Maron, and B. Basavaraj Kerur et al. Can spironolactone mitigate myocardial fibrosis and alter sudden death risk and heart failure symptoms in patients with hypertrophic cardiomyopathy?: A prospective, randomized trial Circulation 128 2013 A16910
79. M.S. Maron, I. Olivotto, and B.J. Maron et al. The case for myocardial ischemia in hypertrophic cardiomyopathy J Am Coll Cardiol 54 2009 866 875
80. F. Cecchi, I. Olivotto, and R. Gistri et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy N Engl J Med 349 2003 1027 1035
81. B.J. Maron, T.S. Haas, and K.M. Shannon et al. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy Heart Rhythm 6 2009 993 997
82. B.J. Maron, C. Semsarian, and W.-K. Shen et al. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy Heart Rhythm 6 2009 599 602
83. G. Lin, R.A. Nishimura, and B.J. Gersh et al. Device complications and inappropriate implantable cardioverter-defibrillator shocks in patients with hypertrophic cardiomyopathy Heart 95 2009 709 714
84. R.G. Hauser, W.H. Maisel, and P.A. Friedman et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management Circulation 123 2011 358 363
85. G. Boriani, B.J. Maron, and W.-K. Shen et al. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation 110 2004 e438 e442
86. R.G. Hauser The subcutaneous implantable cardioverter-defibrillator: should patients want one? J Am Coll Cardiol 61 2013 20 22
87. B.J. Maron, J.J. Doerer, and T.S. Haas et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the U.S., 1980-2006 Circulation 119 2009 1085 1092
88. B.J. Maron, R.A. Friedman, P. Kligfield on behalf of the American Heart Association Council on Clinical Cardiology, Advocacy Coordination Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Surgery and Anesthesia, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, Council on Quality of Care and Outcomes Research, and American College of Cardiology Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in general healthy populations of young people (12-25 years of age) Circulation 2014 10.1161/CIR.0000000000000025 In press
89. P. Melacini, C. Basso, and A. Angelini et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy Eur Heart J 31 2010 2111 2123
90. I. Olivotto, F. Cecchi, and S.A. Casey et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy Circulation 104 2001 2517 2524
91. B.J. Maron, I. Olivotto, and P. Bellone et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy J Am Coll Cardiol 39 2002 301 307
92. P. Di Donna, I. Olivotto, and S.D. Delcre et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression Europace 12 2010 347 355
93. T. Kubo, H. Kitaoka, and M. Okawa et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. RESULTS: from Kochi Ryoma study Circ J 73 2009 1599 1605
94. S. Nistri, I. Olivotto, and M.S. Maron et al. Beta-blockers for prevention of exercise-induced left ventricular outflow tract obstruction in hypertrophic cardiomyopathy Am J Cardiol 110 2012 715 719
95. M.V. Sherrid, I. Barac, and W.J. McKenna et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J Am Coll Cardiol 45 2005 1251 1258
96. R. Coppini, C. Ferrantini, and L. Yao et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy Circulation 127 2013 575 584
97. M.Y. Desai, A. Bhonsale, and N.G. Smedira et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction Circulation 128 2013 209 216
98. A. Woo, W.G. Williams, and R. Choi et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy Circulation 111 2005 2033 2041
99. W. Ball, J. Ivanov, and H. Rakowski et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment J Am Coll Cardiol 58 2011 2313 2321
100. C.J. McLeod, S.R. Ommen, and M.J. Ackerman et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy Eur Heart J 28 2007 2583 2588
101. S.F. Nagueh, B.M. Groves, and L. Schwartz et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter north american registry J Am Coll Cardiol 58 2011 2322 2328
102. P.A. Noseworthy, M.A. Rosenberg, and M.A. Fifer et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy Am J Cardiol 104 2009 128 132
103. F.J. ten Cate, O.I. Soliman, and M. Michels et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution Circ: Heart Fail 3 2010 362 369
104. S. Agarwal, E.M. Tuzcu, and M.Y. Desai et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy J Am Coll Cardiol 55 2010 823 834
105. F.A. Cuoco, W.H. Spencer III, and V.L. Fernandes et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy J Am Coll Cardiol 52 2008 1718 1723
106. U.S. Valeti, R.A. Nishimura, and D.R. Holmes et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 49 2007 350 357
107. S.F. Nagueh, B.M. Groves, and L. Schwartz et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy J Am Coll Cardiol 58 2011 2322 2328
108. I. Olivotto, S.R. Ommen, and M.S. Maron et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 50 2007 831 834
109. B.J. Maron, and M.E. Josephson Long-term consequences of the right ventricular pacing mania of the 1990s for obstructive hypertrophic cardiomyopathy Am J Cardiol 113 2014 191 192
110. B.J. Maron, R.A. Nishimura, and W.J. McKenna et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-Pathy) Circulation 99 1999 2927 2933
111. E.J. Rowin, B.J. Maron, and I. Olivotto et al. Progressive heart failure is uncommon in patients with nonobstructive hypertrophic cardiomyopathy Circulation 128 2013 A14979
112. J.B. Geske, P. Sorajja, and R.A. Nishimura et al. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization Circulation 116 2007 2702 2708
113. I. Olivotto, B.J. Maron, and E. Appelbaum et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy Am J Cardiol 106 2010 261 267
114. M.S. Maron, B.M. Kalsmith, and J.E. Udelson et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy Circ: Heart Fail 3 2010 574 579
115. B.J. Maron, T.S. Haas, and M.S. Maron et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance Am J Cardiol 113 2014 1394 1400
116. P. Santangeli, L. Di Biase, and S. Themistoclakis et al. Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence Circ Arrhythm Electrophysiol 6 2013 1089 1094
117. T.J. Bunch, T.M. Munger, and P.A. Friedman et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy J Cardiovasc Electrophysiol 19 2008 1009 1014
118. B.J. Maron, M.S. Maron, and B.A. Maron et al. Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy J Am Coll Cardiol 57 2011 2454 2456
119. B.J. Maron Recognition of hypertrophic cardiomyopathy as a contemporary, relatively common and treatable disease: International Summit V Am J Cardiol 113 2014 739 744